The OrthoEvra Patch

FLAME LECTURE: 149C
KIM/ROME 9.1.15
Learning Objectives

- Describe the mechanism of action and effectiveness of contraceptive methods
- Counsel the patient regarding the benefits, risks, and uses for each contraceptive method
- Describe barriers to effective contraceptive use and to the reduction of unintended pregnancy
- Prerequisites:
  - NONE
- See also – for closely related topics
  - FLAMEs on Barrier methods / CHCs – NuvaRing / CHCs – Patch / Depo-provera / Mirena / ParaGard / Nexplanon
  - FLAME 213: Menstrual Cycle
  - FLAME 149A2: The Contraceptive Counseling Visit
OVERVIEW

- The Patch is a type of CHC in that it contains both estrogen and a progestin.
- Other combined hormonal contraceptives (CHCs) include:
  - Combined oral contraceptives (COCs)
  - The NuvaRing
Mechanisms of action of the Patch

- **Primary function:** **INHIBITS OVULATION** (Estrogen-mediated)
  - Inhibits LH surge to prevent ovulation
  - Suppresses FSH to suppress ovarian folliculogenesis
  - See FLAME 213: Menstrual cycle for better understanding
- **Secondary functions** (all three are progesterone-mediated)
  - Thins endometrial lining to become unfavorable for implantation
  - Alterations in cervical mucus to become less permeable to penetration by sperm
  - Impairment of normal tubal motility and peristalsis
TRANSDERMAL CONTRACEPTIVE PATCH

- 2 x 2 cm square patch to be placed on the buttock, abdomen, upper arm, or upper torso and changed every 7 days for 3 weeks followed by one patch-free week
- Contains 0.75mg ethinyl estradiol (EE) + 6mg norelgestromin
  - 20 mcg EE and 150 mcg norelgestromin released daily
  - Greater average overall ("area under the curve") EE concentration than COC users, but 25% lower peak EE concentrations
- Advantages over COCs
  - Lower peak doses by avoiding first pass metabolism
  - Constant plasma hormone levels with no peaks/troughs
  - Doesn’t require daily administration which may improve compliance
- Disadvantages compared to COCs
  - **CANNOT be used for patients > 200 lbs** (decreased absorption)
  - Not as well studied for “continuous” or extended-cycle administration
OTHER ADVANTAGES

- Easy to obtain, relatively inexpensive (with insurance)
- Bypasses GI tract/first pass metabolism
- Can be used in the treatment of menstrual cycle disorders
  - Menorrhagia, dysmenorrhea, PMS and PMDD symptoms (not first-line)
- Can be used in the treatment of hyperandrogenism
  - Decreases acne and hirsutism
- Can be used in the treatment of gynecologic disorders
  - Can decrease AUB and pain from leiomyomas and endometriosis
- Cancer risk reduction
  - Decreased risk of endometrial, ovarian, colon cancers
  - Conflicting data on similar reduction in risk in BRCA ovarian cancer
OTHER DISADVANTAGES

- Perfect use is harder to achieve than with LARCs
- It does not protect against STIs
- It can cause breakthrough bleeding from tissue breakdown of endometrium
  - More common in lower doses of estrogen because normally estrogen will stabilize endometrium
- Amenorrhea can occur with continuous and extended regimens, as well as standard preparations
- Some reports of decreased libido, however data is mixed
- Increased risks of HTN, VTE, and stroke (but significantly less risk than pregnancy-associated risks)
- Increased metabolic concerns
  - **Estrogen**: increases serum triglycerides, HDL, and lowers LDL
  - **Progestin**: increases LDL, lowers HDL (particularly androgenic progestins)
- Contrary to popular belief, there is **NO** evidence of significant weight gain with CHCs!
CONTRAINDICATIONS

- Smoking over the age of 35
- Diabetes > 20 years OR any complications (nephropathy, neuropathy, retinopathy, etc)
- HTN
- Hx of VTE/Stroke, or any known thrombogenic mutations (including SLE with APAs)
- Hx of ischemic heart disease or complicated valvular heart disease (pulmonary HTN, risk for A fib, history of subacute bacterial endocarditis) or multiple risk factors or history of peripartum cardiomyopathy.
- Hx of migraines: new onset with OCP, > 35 years of age, OR migraines + aura at any age
- Hx of Breast Cancer
- Liver disease: acute viral hepatitis, severe cirrhosis, Hepatocellular adenoma, or malignant hepatoma, gallbladder disease (if still has gallbladder), COC-related cholestasis
- Postpartum < 21 days (42 days if other VTE risk factors)
QUICK START METHOD  (not currently using any method)

- If LMP <5 days ago: Place the Patch
- If LMP 5-8 days ago: Neg UPreg → Offer Plan B → Place the Patch → UPreg in 3 weeks
- If LMP 5-10 days ago: Neg UPreg → Offer Ella → Place the Patch → UPreg in 3 weeks
- If LMP >10 days ago: Place the Patch → UPreg in 2 weeks

Unlike the IUDs, it is OK to start this method even if there is a chance of pregnancy, because it is not teratogenic. If the Upreg turns positive, then stop using and make an appointment with your OB to discuss pregnancy options.
50% of pregnancies in the US are unplanned, and ~50% of these are terminated

Most women with unintended pregnancies report using some form of contraception

Reasons for nonuse of contraception include:
- Thinking they could not get pregnant at that time (33%)
- Not minding if they got pregnant (30%)
- Partner did not want to use contraception (22%)
- Side effects (16%)
- Access problems (10%)

No one method is perfect, but factors to consider include efficacy, convenience, duration of action, reversibility and return to fertility, effect on uterine bleeding, cost, accessibility, and medical contraindications

Clarify needs, concerns, expectations: preferences, childbearing plans, pattern of sexual activity, social/cultural factors, ability to use method successfully, cost, ease of repeat administration, attitudes about unintended pregnancy

67% of couples using CHCs continue to use that method for one year
FERTILITY after CHC discontinuation

- Commonly, menses will return within 30 days after stopping CHCs.
- Menses and full fertility should return to normal in almost all women within 90 days.
- If women do not menstruate 3 months after stopping this method, they should undergo the same workup for amenorrhea as any woman with amenorrhea.
IMPORTANT LINKS

- PRACTICE BULLETIN 73 - Use of hormonal contraception in women with coexisting medical conditions
- PRACTICE BULLETIN 110 - Noncontraceptive uses of hormonal contraceptives
- CDC US Medical Eligibility Criteria for Contraceptive Use: Summary Chart
- US Selected Practice Recommendations for Contraceptive Use, 2013
OTHER REFERENCES

1. UpToDate “Overview of the use of estrogen-progestin contraceptives” Sept 2015
2. UpToDate “Risks and side effects associated with estrogen-progestin contraceptives” Sept 2015
3. UpToDate “Contraceptive vaginal ring” Sept 2015
4. UpToDate “Transdermal contraceptive patch” Sept 2015
5. UpToDate “Counseling women considering combined hormonal contraception” Sept 2015
6. UpToDate “Overview of contraception” Sept 2015